PLK4
ENSG00000142731
Target class
Kinase
Chromosome
4
Approved drugs
0
Clinical candidates (approved and in development)
3
- Approved drugs
- 0
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- Yes
- Other names
- Sak
- Target name
- PLK4
- Gene name
- Polo like kinase 4
- Gene symbol
- PLK4
- Previous gene symbols
- STK18
- Protein name
- Serine/threonine-protein kinase PLK4 (EC 2.7.11.21) (Polo-like kinase 4) (PLK-4) (Serine/threonine-protein kinase 18) (Serine/threonine-protein kinase Sak)
- Gene biotype
- Protein coding
- Gene family
- Polo like kinase family
- Target class
- Kinase
- Target type
- Human gene
- Tissues expressed in
- 20
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 29.75
- Tissue specificity (Gini)
- 0.674
- Tissue specificity (tau)
- 0.95
- KEGG gene identifiers
- hsa:10733
- Protein interaction confidence
- 0.826686
- Protein interaction partners
- 70
- R-HSA-2565942
- R-HSA-380259
- R-HSA-380270
- R-HSA-380284
- R-HSA-380320
- R-HSA-5620912
- R-HSA-8854518
- End position
- 127899224
- Start position
- 127880890
- Chromosome
- 4
- Strand
- Forward
- Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriole . Nucleus, nucleolus . Cleavage furrow . Cytoplasm, cytoskeleton, microtubule organizing center, centrosome . Note=Component of the deuterosome, a structure that promotes de novo centriole amplification in multiciliated cells that can generate more than 100 centrioles. Associates with centrioles throughout the cell cycle. According to PubMed:16244668, it is not present at cleavage furrows.
- Centrosome
- PubMed 22020124
- PubMed 27246242
- PubMed 27796307
- PubMed 30804208
- PubMed 32433990
- PubMed 16244668
- Tissue specificity (tau)
- 0.949516
- Expression inequality (Gini)
- 0.674154
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 29.75
- Testis
- 24.17
- Cells - Cultured fibroblasts
- 6.68
- Esophagus - Mucosa
- 4.5
- Skin - Not Sun Exposed (Suprapubic)
- 2.82
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes29.75
- Testis24.17
- Cells - Cultured fibroblasts6.68
- Esophagus - Mucosa4.5
- Skin - Not Sun Exposed (Suprapubic)2.82
- Skin - Sun Exposed (Lower leg)2.75
- Vagina2.23
- Small Intestine - Terminal Ileum2.14
- Spleen1.88
- Colon - Transverse1.58
- Ovary1.43
- Adipose - Subcutaneous1.43
- Cervix - Endocervix1.29
- Nerve - Tibial1.24
- Breast - Mammary Tissue1.23
- Cervix - Ectocervix1.21
- Lung1.18
- Uterus1.12
- Thyroid1.06
- Fallopian Tube1.05
- Bladder0.98
- Prostate0.95
- Adrenal Gland0.91
- Minor Salivary Gland0.9
- Brain - Nucleus accumbens (basal ganglia)0.87
And 29 more, listed on the interactive page.
- GO:0007099
- GO:0046601
- GO:0060271
- GO:0005813
- GO:0005814
- GO:0005829
- GO:0120098
- GO:0004674
- GO:0005515
- GO:0042802
- GO:0106310
Related records
Trials (203)
- A Bioequivalence Study Of AG-013736 Tablets In Healthy Volunteers
- A Bioequivalence Study Of AG-013736 Tablets Under Fed Conditions In Healthy Volunteers
- A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer
- A Multiple Ascending Dose Study of R1530 in Patients With Advanced Solid Tumors.
- A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors
- A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetaxel.
- A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus
- A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy
- A Randomized Phase II Clinical Trial on the Efficacy of Axitinib as a Monotherapy or in Combination With Lomustine for the Treatment of Patients With Recurrent Glioblastoma
- A Study Combining FOLFOX or FOLFIRI With AG-013736 or Bevacizumab (Avastin) in Patients With Metastatic Colorectal Cancer After Failure Of One First Line Regimen
- A Study In Patients With Advanced Solid Tumor
- A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer.
- A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma
- A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma
- A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma
- A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)
- A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)
- A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)
- A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy
- A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
Drugs (4)
- Axitinib
- CFI-400945 Serine/threonine-protein kinase PLK4 inhibitor
- Ocifisertib Serine/threonine-protein kinase PLK4 inhibitor
- RG-1530 Serine/threonine-protein kinase PLK4 inhibitor